BR112015010693A2 - inibidores de tirosina quinase de bruton - Google Patents

inibidores de tirosina quinase de bruton

Info

Publication number
BR112015010693A2
BR112015010693A2 BR112015010693A BR112015010693A BR112015010693A2 BR 112015010693 A2 BR112015010693 A2 BR 112015010693A2 BR 112015010693 A BR112015010693 A BR 112015010693A BR 112015010693 A BR112015010693 A BR 112015010693A BR 112015010693 A2 BR112015010693 A2 BR 112015010693A2
Authority
BR
Brazil
Prior art keywords
compounds
tyrosine kinase
kinase inhibitors
bruton tyrosine
diseases associated
Prior art date
Application number
BR112015010693A
Other languages
English (en)
Inventor
Mertz Eric
Javier Lopez-Tapia Francisco
Dominique Romyr
So Sung-Sau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015010693A2 publication Critical patent/BR112015010693A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

1/1 resumo inibidores de tirosina quinase de bruton esse pedido descreve compostos de acordo com a fórmula i genérica, em que todas as variáveis são definidas tal como aqui descritas, os quais inibem btk. os compostos aqui descritos são úteis para modular a atividade de btk e tratar doenças associadas com a atividade excessiva de btk. os compostos são ainda úteis para o tratamento de doenças inflamatórias e doenças autoimunes associadas com a proliferação de células b anormais, tal como artrite reumatóide. também são descritas composições contendo os compostos de fórmula i e pelo menos um veículo, diluente ou excipiente.
BR112015010693A 2012-11-16 2013-11-13 inibidores de tirosina quinase de bruton BR112015010693A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261727130P 2012-11-16 2012-11-16
PCT/EP2013/073667 WO2014076104A1 (en) 2012-11-16 2013-11-13 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
BR112015010693A2 true BR112015010693A2 (pt) 2017-07-11

Family

ID=49584724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010693A BR112015010693A2 (pt) 2012-11-16 2013-11-13 inibidores de tirosina quinase de bruton

Country Status (13)

Country Link
US (1) US9458105B2 (pt)
EP (1) EP2920162B1 (pt)
JP (1) JP6088063B2 (pt)
KR (1) KR101713465B1 (pt)
CN (1) CN104812746B (pt)
AR (1) AR093478A1 (pt)
BR (1) BR112015010693A2 (pt)
CA (1) CA2890671A1 (pt)
HK (1) HK1212689A1 (pt)
MX (1) MX2015006162A (pt)
RU (1) RU2015120216A (pt)
TW (1) TW201425297A (pt)
WO (1) WO2014076104A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
CN109369619A (zh) * 2018-10-04 2019-02-22 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型b及其制备方法
CN109485636A (zh) * 2018-10-04 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途
CN109172592A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种抗肿瘤药物组合物
CN109180643A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型a及其制备方法
CN109336864A (zh) * 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型n及其制备方法
CN109180642A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类btk抑制剂及其应用
CN109336863A (zh) * 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种新型酞嗪酮类btk抑制剂、制备及其应用
CN109293635A (zh) * 2018-10-04 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的p晶型及其制备方法
CN109288830A (zh) * 2018-10-04 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型酞嗪酮类化合物联合用药物组合物
CN109180644A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的甲磺酸盐及其制备方法与用途
CN109481441A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109331005A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和氟酞嗪类btk抑制剂联合用药物组合物及其应用
CN109481444A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和酞嗪类btk抑制剂联合用药物组合物及其应用
CN109172562A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109276571A (zh) * 2018-10-31 2019-01-29 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109223759A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394766A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481443A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394765A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109288841A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109331018A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109481442A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
JP2023501238A (ja) * 2019-10-30 2023-01-18 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤としての縮合ピリダジンまたはピリミジン
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045750A (ja) * 1995-09-20 1998-02-17 Takeda Chem Ind Ltd アゾール化合物、その製造方法及び用途
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
MX2010008197A (es) * 2008-02-05 2010-08-23 Hoffmann La Roche Nuevas piridinonas y piridazinonas.
PE20100851A1 (es) * 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CN106220614B (zh) * 2010-09-01 2019-07-16 吉利德康涅狄格有限公司 吡啶酮/吡嗪酮、其制备方法及使用方法
JP5859640B2 (ja) * 2011-05-17 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ阻害剤
CA2841801A1 (en) * 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
BR112014010460A2 (pt) * 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112014013582A2 (pt) * 2011-12-09 2017-06-13 Hoffmann La Roche inibidores de quinase de tirosina de bruton
CA2881761A1 (en) * 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibitors of bruton's tyrosine kinase
CN105051028B (zh) * 2013-03-05 2017-06-09 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
US9663494B2 (en) * 2013-03-05 2017-05-30 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
BR112015029972A2 (pt) * 2013-07-03 2017-07-25 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto

Also Published As

Publication number Publication date
AR093478A1 (es) 2015-06-10
US9458105B2 (en) 2016-10-04
CN104812746A (zh) 2015-07-29
JP6088063B2 (ja) 2017-03-01
KR20150084061A (ko) 2015-07-21
TW201425297A (zh) 2014-07-01
JP2015537016A (ja) 2015-12-24
WO2014076104A1 (en) 2014-05-22
KR101713465B1 (ko) 2017-03-07
EP2920162B1 (en) 2017-04-19
EP2920162A1 (en) 2015-09-23
CN104812746B (zh) 2017-03-08
MX2015006162A (es) 2015-08-14
CA2890671A1 (en) 2014-05-22
HK1212689A1 (zh) 2016-06-17
US20150291525A1 (en) 2015-10-15
RU2015120216A (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
BR112015010693A2 (pt) inibidores de tirosina quinase de bruton
BR112015007513A2 (pt) inibidores de tirosina quinase de bruton
BR112014003582A2 (pt) inibidores da tirosina quinase de bruton
BR112014013582A2 (pt) inibidores de quinase de tirosina de bruton
BR112013003114A2 (pt) inibidores de tirosina quinase de bruton
MX345170B (es) Inhibidores de la tirosina-cinasa de bruton.
BR112015021806A2 (pt) inibidores de tirosina cinase de bruton
BR112015021677A2 (pt) inibidores de tirosina quinase de bruton
BR112012024117A2 (pt) inibidores de pirrolopirazina quinase
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
CU20170094A7 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-0na
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112015032595A8 (pt) inibidores de ido
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
UA113543C2 (xx) Сполуки та композиції для модулювання egfr активності
BR112013000107A2 (pt) aminopirazoloquinazolinas
MX2011008643A (es) Inhibidores de tirosina cinasa de bruton.
BR112015001759A2 (pt) agentes de modulação de atx
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112015013762A2 (pt) derivados de tiazol como inibidores de tirosina cinase de bruton
EA201790207A1 (ru) Новые замещенные пиримидиновые соединения
MX366839B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
BR112014008616A2 (pt) compostos antivirais
BR112015025250A2 (pt) inibidores de tirosina quinase de bruton

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements